| Budget Amount *help |
¥187,200,000 (Direct Cost: ¥144,000,000、Indirect Cost: ¥43,200,000)
Fiscal Year 2014: ¥33,930,000 (Direct Cost: ¥26,100,000、Indirect Cost: ¥7,830,000)
Fiscal Year 2013: ¥35,620,000 (Direct Cost: ¥27,400,000、Indirect Cost: ¥8,220,000)
Fiscal Year 2012: ¥37,310,000 (Direct Cost: ¥28,700,000、Indirect Cost: ¥8,610,000)
Fiscal Year 2011: ¥36,920,000 (Direct Cost: ¥28,400,000、Indirect Cost: ¥8,520,000)
Fiscal Year 2010: ¥43,420,000 (Direct Cost: ¥33,400,000、Indirect Cost: ¥10,020,000)
|
|---|
| Outline of Final Research Achievements |
Based on the proteasome-independent potentials, human cancer stem cells (CSCs) were visualized and isolated to identify the specific inhibitor combined with conventional anti-cancer drugs. CSCs facilitated metastatic activities with niche formation by recruitment of macrophages in vivo. Additionally, we synthesized the transgenic mice with monitoring of the proteasome activity to reveal in vivo mechanisms of stemness and carcinogenesis of various malignancies including pancreatic cancer.
To characterize the biological significance of the cell cycle phases in CSCs, we used the visualizing system by ‘fluorescence ubiquitin-based cell cycle indicator’ (Fucci). This system allowed the G2M phase as green whereas G1 phase as red colors. We were able to identify therapy-resistant CSCs in G1 phase, although cell mobility and invasion linked with G2M phase. Several genes were characterized and focused on the novel therapeutic targets.
|
